Research Article
Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
Table 1
Blood test results of examined MPN patients according to JAK2 mutant allele burden.
| | MPN | 2V617P | CD34+ (cells/μL) | Leukocytes (109/L) | Thrombocytes (109/L) | Erythrocytes (1012/L) | MCV | Hemoglobin (g/L) |
| | ЕТ | 0 | 6.3 (±3.4) | 8.77 (±2.4) | 1110 (±358) | 4.6 (±0.4) | 88.7 (±3.7) | 134.1 (±14) | | <50% | 6.2 (±6.1) | 9.1 (±3.5) | 815 (±249)2 | 5 (±0.53)2 | 87 (±3.9) | 142 (±13)1 |
| | PV | Sec Er | 2.5 (±0.7) | 7.25 (±1.9) | 203 (±46) | 5.34 (±0.4) | 89.8 (±3.6) | 161.6 (±13) | | <50% | 6.3 (±4.6)1 | 12.2 (±3.9)2 | 807 (±349)2 | 6.1 (±0.8)2 | 82 (±8.8)2 | 158.4 (±15) | | >50% | 9.4 (±8.2)1 | 17.3 (±9.5)2 | 631 (±270)2 | 6.5 (±0.9)2 | 74.6 (±8.8)2 | 152.4 (±17) |
| | PMF | 0 | 29.8 (±37) | 8.8 (±3.1) | 905 (±320) | 4.4 (±0.44) | 87.1 (±5.6) | 126.5 (±17) | | <50% | 99 (±212) | 12.9 (±5.1)2 | 804 (±364) | 4.9 (±0.8)1 | 84 (±6.2) | 138 (±14)1 | | >50% | 126 (±158) | 14.2 (±5.5)2 | 509 (±331)2 | 5.34 (±1.3)2 | 77.7 (±11)2 | 129.1 (±20) |
|
|
-test: , versus MPNs without JAK2 mutation (0) and secondary erythrocytosis (Sec Er).
|
